SEC Form 4 · accession 0001209191-16-112563
KYNTRA BIO, INC. · KYNB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Frank H Valone M.D.
Officer — Chief Medical Officer
Period of report
Apr 1, 2016
Accepted (ET)
Apr 4, 2016 · 6:53 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000921299
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 1, 2016 | M | 10,750 | $3.925 | A | 115,434 | D | |
| Common StockF1,F2 | Apr 1, 2016 | S | 10,550 | $21.104 | D | 104,884 | D | |
| Common StockF1 | Apr 1, 2016 | S | 200 | $21.47 | D | 104,684 | D | |
| Common Stock | holding | — | — | — | 4,000 | I | By Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $3.925 | Apr 1, 2016 | M | 10,750 | D | — | Aug 11, 2019 | Common Stock | 10,750 | 2,722 | D |
Explanation of responses
- F1Shares sold pursuant to a 10b5-1 plan.
- F2The shares were sold at prices between $20.47 and $21.46. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3Fully vested.